Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by City Center Advisors LLC

City Center Advisors LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 30.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 4,577 shares of the biopharmaceutical company’s stock after selling 2,020 shares during the quarter. City Center Advisors LLC’s holdings in Gilead Sciences were worth $423,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Avior Wealth Management LLC lifted its position in Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares during the period. Concord Asset Management LLC VA raised its stake in shares of Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 111 shares during the last quarter. TFB Advisors LLC lifted its holdings in shares of Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after buying an additional 116 shares during the period. Sumitomo Life Insurance Co. boosted its stake in shares of Gilead Sciences by 0.7% in the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 117 shares during the last quarter. Finally, FDx Advisors Inc. raised its position in Gilead Sciences by 2.2% during the third quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock valued at $450,000 after acquiring an additional 117 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock valued at $41,902,086 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $89.88 on Monday. The stock has a 50 day moving average price of $91.94 and a 200 day moving average price of $83.39. The stock has a market cap of $112.01 billion, a PE ratio of 998.67, a P/E/G ratio of 2.24 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the company earned $2.29 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.43%. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price on the stock. Finally, Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.